Published in Lancet on January 22, 1977
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
Neuropsychological syndromes in presenile dementia due to cerebral atrophy. J Neurol Neurosurg Psychiatry (1986) 1.83
The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.50
The cholinergic system and Parkinson disease. Behav Brain Res (2010) 1.38
Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry (1986) 1.36
Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev (2009) 1.33
A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 1.25
Cholinergic modulation of visual attention and working memory: dissociable effects of basal forebrain 192-IgG-saporin lesions and intraprefrontal infusions of scopolamine. Learn Mem (2004) 1.24
Amyloid-β as a modulator of synaptic plasticity. J Alzheimers Dis (2010) 1.22
Tetrahydrobiopterin metabolism in senile dementia of Alzheimer type. J Neurol Neurosurg Psychiatry (1983) 1.15
Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. J Neural Transm (Vienna) (2011) 1.09
Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol (2008) 1.06
Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum Mol Genet (2008) 1.06
Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core. Br Med J (Clin Res Ed) (1981) 1.03
Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst (2010) 1.01
Altered levels of acetylcholinesterase in Alzheimer plasma. PLoS One (2010) 0.99
Genetic risk factors in Alzheimer's disease. Mol Pathol (1998) 0.97
Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci (2011) 0.97
Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study. J Neural Transm (Vienna) (2012) 0.95
Is the loss of cerebral cortical choline acetyl transferase activity in Alzheimer's disease due to degeneration of ascending cholinergic nerve cells. J Neurol Neurosurg Psychiatry (1982) 0.92
Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry (1987) 0.92
Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Hum Genet (2003) 0.91
Focal cerebral hypoperfusion and selective cognitive deficit in dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry (1987) 0.90
Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis. Horm Behav (2009) 0.89
Extensive lesions of cholinergic basal forebrain neurons do not impair spatial working memory. Learn Mem (2004) 0.88
Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proc Natl Acad Sci U S A (1990) 0.88
Neuropathological changes in brain cortex and hippocampus in a rat model of Alzheimer's disease. Iran Biomed J (2011) 0.86
Is there a neuropathology difference between mild cognitive impairment and dementia? Dialogues Clin Neurosci (2009) 0.85
Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination. Psychopharmacology (Berl) (2004) 0.84
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol (2004) 0.84
Early neurone loss in Alzheimer's disease: cortical or subcortical? Acta Neuropathol Commun (2015) 0.83
Morphological and biochemical changes in the cholinergic and monoaminergic systems in Alzheimer-type dementia. Acta Neuropathol (1986) 0.83
Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol (2002) 0.83
Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol (2004) 0.83
Involvement of 5-HT(2A/2B/2C) receptors on memory formation: simple agonism, antagonism, or inverse agonism? Cell Mol Neurobiol (2002) 0.81
Lentiviral infection of rhesus macaques causes long-term injury to cortical and hippocampal projections of prostaglandin-expressing cholinergic basal forebrain neurons. J Neuropathol Exp Neurol (2012) 0.80
Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J Neural Transm (Vienna) (2012) 0.80
Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.79
An innovative intervention for the treatment of cognitive impairment-Emisymmetric bilateral stimulation improves cognitive functions in Alzheimer's disease and mild cognitive impairment: an open-label study. Neuropsychiatr Dis Treat (2015) 0.79
Increased in vitro phosphorylation of a Mr 60,000 protein in brain from patients with Alzheimer disease. Proc Natl Acad Sci U S A (1986) 0.79
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Ther Adv Drug Saf (2015) 0.78
The effect of prenatal nicotine on mRNA of central cholinergic markers and hematological parameters in rat fetuses. Int J Dev Neurosci (2008) 0.78
Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation. Mol Cell Biol (2008) 0.78
Pharmacological models in Alzheimer's disease research. Dialogues Clin Neurosci (2000) 0.77
Changes in the human visual evoked potential caused by the anticholinergic agent hyoscine hydrobromide: comparison with results in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1986) 0.77
Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia. Br J Pharmacol (2015) 0.76
Drugs for dementia: the first year. An audit of prescribing practice. Ulster Med J (2000) 0.75
Effects of training in the Morris water maze on the spatial learning acquisition and VAChT expression in male rats. Daru (2011) 0.75
Charting the conquest of senility. Bull N Y Acad Med (1982) 0.75
Clinical pharmacology and therapeutics. Postgrad Med J (1991) 0.75
L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors. Br J Pharmacol (1992) 0.75
Quantifying the quiet epidemic: Diagnosing dementia in late 20(th)-century Britain. Hist Human Sci (2014) 0.75
Cortical vasoactive intestinal peptide in relation to dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (1985) 0.75
CSF choline levels in groups of patients with cranial trauma or extrapyramidal disorders. J Neurol Neurosurg Psychiatry (1984) 0.75
Age-dependent biochemical dysfunction in skeletal muscle of triple-transgenic mouse model of Alzheimer`s disease. Curr Alzheimer Res (2015) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry (1968) 18.69
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Observations on the brains of demented old people. J Neurol Sci (1970) 6.99
Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature (1982) 4.93
Observations on the brains of non-demented old people. J Neurol Sci (1969) 4.06
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
Staging and natural history of cerebrovascular pathology in dementia. Neurology (2012) 2.61
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 2.47
Prevalence rates of dementia in an ageing population: are low rates due to the use of insensitive instruments? Age Ageing (1990) 2.45
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci (1990) 2.24
Correlation between scores for dementia and counts of 'senile plaques' in cerebral grey matter of elderly subjects. Nature (1966) 2.23
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Autism as a disorder of neural information processing: directions for research and targets for therapy. Mol Psychiatry (2004) 2.19
The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci (1977) 2.07
Histochemical aspects of five limb muscles in old age. An autopsy study. J Neurol Sci (1971) 2.03
The effects of ageing and of cachexia upon skeletal muscle. A histopathological study. J Neurol Sci (1969) 2.00
Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology (1999) 2.00
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91
Letter: Unusual cardiac and neurological reactions to narcotics. Lancet (1973) 1.90
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology (2000) 1.85
A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res (1981) 1.85
Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci (1977) 1.83
Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol (1978) 1.82
Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci (1981) 1.78
Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet (1994) 1.77
Radiation myelitis of the dorsolumbar spinal cord. Radiology (1969) 1.64
Granulovacuolar degeneration of hippocampal pyramidal cells. J Pathol (1972) 1.59
A neuropathological study of vascular factors in late-life depression. J Neurol Neurosurg Psychiatry (2001) 1.53
Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci (1983) 1.51
Data on the distribution of fibre types in five human limb muscles. An autopsy study. J Neurol Sci (1971) 1.51
The contemporary natural history of mental disorder in old age. Br J Psychiatry (1982) 1.50
Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med (1992) 1.49
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain (1999) 1.48
The extensor digitorum brevis: histological and histochemical aspects. J Neurol Neurosurg Psychiatry (1972) 1.47
Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry (2001) 1.44
Central pontine myelinolysis. Two cases with associated electrolyte disturbance. Q J Med (1976) 1.40
Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer (1992) 1.36
Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet (1986) 1.35
The cholinergic hypothesis--ten years on. Br Med Bull (1986) 1.31
Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. Neuropathol Appl Neurobiol (2006) 1.29
Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav (2002) 1.28
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am J Pathol (1994) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology (2003) 1.28
An evaluation of lymphadenectomy in the treatment of malignant testicular germ cell neoplasms. J Urol (1969) 1.26
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci (1991) 1.24
Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology (2000) 1.22
Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer's disease. J Neurol Sci (1977) 1.20
Blessed-Roth Dementia Scale (DS). Psychopharmacol Bull (1988) 1.20
The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry (1994) 1.18
An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology (1994) 1.18
Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol (1998) 1.17
Clinically and neuropathologically distinct form of dementia in the elderly. Lancet (1989) 1.16
Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci Lett (1982) 1.14
Subacute "poliomyelitis" and Hodgkin's disease. J Neurol Sci (1969) 1.11
Amyloid and senile plaques and cerebral blood vessels. A semi-quantitative investigation of a possible relationship. J Neurol Sci (1983) 1.11
Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) (1981) 1.11